urnals. He is the
editor of the widely read textbook, "Chronic Kidney Disease, Dialysis and
Transplantation," and has over 200 scientific papers to his credit. Dr.
Pereira is Chairman of the Board of the Harvard-MIT Biomedical Enterprise
Program, a member of the Board of Directors of Satellite Health Care and
the National Kidney Foundation, and an advisor to several other
organizations. Dr. Pereira is a graduate of both St. John's Medical College
and Post Graduate Institute of Medical Education and Research in India. He
received his M.B.A. from Kellogg Graduate School of Management at
Northwestern University.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the
development and commercialization of innovative treatments for endocrine
disorders, such as diabetes and osteoporosis. Biodel's product candidates
are developed by using VIAdel(TM) technology, which reformulates existing
FDA- approved peptide drugs. The Company's lead product candidate,
VIAject(TM), is a rapid-acting injectable meal-time insulin in development
for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is
currently being tested in two pivotal Phase III clinical trials. Biodel's
pipeline also includes VIAtab(TM), a sublingual tablet formulation of
insulin in Phase I clinical trials and two osteoporosis product candidates
in pre-clinical studies. For further information regarding Biodel, please
visit the Company's website at http://www.biodel.com.
Safe Harbor
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other then statements of historical facts, including statements
regarding our strategy, future operations, future financial position,
future revenues, projected costs, prospects, plans and objectives of
management are forward- looking statements. The words "anticipates,"
"believes,"
'/>"/>
SOURCE Biodel, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community2.
Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board3.
Hank Plain Joins Morgenthaler Ventures as Partner4.
Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team5.
Senior Research Analyst Richard Evans Joins AVOS Life Sciences6.
Dan Broderick Joins Prolog Ventures as Partner7.
Ingenuity Systems Joins Biomarkers Consortium8.
Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)9.
Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique10.
Progeniq Joins Microsoft in Bio IT Alliance11.
Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman